Inhibition of bupropion metabolism by selegiline: Mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2256-2266

  Sridar, Chitra ^a   Kenaan, Cesar ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXY 4 (TRIFLUOROMETHYL)COUMARIN; AMFEBUTAMONE; ASPARTIC ACID 64; ASPARTYLVALYLPHENYLALANYLTHREONYLVALYLLEUCYLGLYCYLPROLYLARGININE; CARBON MONOXIDE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2B6; GLUTATHIONE; KETENE DERIVATIVE; PEPTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELEGILINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INACTIVATION; LIQUID CHROMATOGRAPHY; METABOLITE; OXYGENATION; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPARKINSON AGENTS; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ESCHERICHIA COLI; GLUTATHIONE; HEME; HUMANS; HYDROXYLATION; MOLECULAR SEQUENCE DATA; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; PEPTIDES; SELEGILINE; TANDEM MASS SPECTROMETRY;

EID: 84869127435     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046979     Document Type: Article

References (38)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, and Richelson E (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
2. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, and Yeh LT (2007) P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 22:78-87.
3. Bumpus NN, Sridar C, Kent UM, and Hollenberg PF (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795-802.
4. Buters JT, Schiller CD, and Chou RC (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4- trifluoromethylcoumarin. Biochem Pharmacol 46:1577-1584.
5. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
6. Chen Z, Ost TW, and Schelvis JP (2004) Phe393 mutants of cytochrome P450 BM3 with modified heme redox potentials have altered heme vinyl and propionate conformations. Biochemistry 43:1798-1808.
7. Cooper BR, Hester TJ, and Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127-134.
8. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, and Mayeux R (1992) An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 49:305-307.
9. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
10. Foley KF, DeSanty KP, and Kast RE (2006) Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 6:1249-1265.
11. Fowler CJ, Oreland L, and Callingham BA (1981) The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. J Pharm Pharmacol 33:341-347.
12. Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, et al. (2010) Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl) imidazole at 2.0-A resolution. Mol Pharmacol 77:529-538.
13. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, and O'Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136-143.
14. Gerlach M, Youdim MB, and Riederer P (1996) Pharmacology of selegiline. Neurology 47: S137-S145.
15. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216.
16. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
17. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
18. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, and Ingelman-Sundberg M (2001) CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29:1480-1484.
19. Hollenberg PF, Kent UM, and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189-205.
20. Knoll J and Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393-408.
21. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, and Epstein LH (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541-548.
22. Magyar K, Szende B, Lengyel J, and Tekes K (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J Neural Transm Suppl 48:29-43.
23. Miksys S, Lerman C, Shields PG, Mash DC, and Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-132.
24. Miksys SL and Tyndale RF (2002) Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27:406-415.
25. Ortiz de Montellano PR and Komives EA (1985) Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. J Biol Chem 260:3330-3336.
26. Paterson IA, Juorio AV, and Boulton AA (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55:1827-1837.
27. Reynolds GP, Riederer P, Sandler M, Jellinger K, and Seemann D (1978) Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm 43:271-277.
28. Richard IH and Kurlan R (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 49:1168-1170.
29. Riederer P and Youdim MB (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359-1365.
30. Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, and Seemann D (1978) On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 43:217-226.
31. Ritter JL and Alexander B (1997) Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry 9:7-13.
32. Scott EE, White MA, He YA, Johnson EF, Stout CD, and Halpert JR (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301.
33. Sharma U, Roberts ES, and Hollenberg PF (1996) Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. Drug Metab Dispos 24:669-675.
34. Siu EC and Tyndale RF (2008) Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 324:992-999.
35. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
36. Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, and Pelkonen O (2000) Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol 86:215-221.
37. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468.
38. Zhang H, Kenaan C, Hamdane D, Hoa GH, and Hollenberg PF (2009) Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1. J Biol Chem 284:25678-25686.